GlassScriptPhysician profile
Stephanie Rodriguez
NPI 1801561378
$5,882.90
in general payments reported to CMS, 2019-2025
26 companies · $2,726 in 2025
The $2,726 reported for 2025 was more than what 97% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $597 · 2023: $950 · 2024: $1,610 · 2025: $2,726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,285.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,649.63 | 2022-2025 | |
| Ardelyx, INC. | $485.69 | 2023-2025 | Ibsrela |
| Genzyme Corporation | $455.07 | 2022-2025 | |
| Janssen Biotech, INC. | $419.87 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Madrigal Pharmaceuticals | $371.34 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $323.27 | 2023-2025 | Entyvio, Eohilia |
| Lilly USA, LLC | $246.29 | 2024-2025 | Omvoh |
| Aimmune Therapeutics, INC. | $230.60 | 2024-2025 | Zenpep, Vowst |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $201.05 | 2022-2025 | Xifaxan, Plenvu |
| Alnylam Pharmaceuticals INC. | $199.53 | 2023-2025 | Givlaari |
| Regeneron Healthcare Solutions, INC. | $174.22 | 2024-2025 | Dupixent |
| Gilead Sciences, INC. | $152.78 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $136.03 | 2024-2025 | Iqirvo, Bylvay |
| Karl Storz Endoscopy-America | $125.29 | 2022 | |
| Pfizer INC. | $116.01 | 2022-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $109.68 | 2024 | Indigo System |
| Intercept Pharmaceuticals, INC. | $109.24 | 2023-2025 | Ocaliva |
| Celgene Corporation | $76.11 | 2023-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $74.24 | 2022-2023 | |
| Organon LLC | $64.86 | 2023-2025 | Hadlima |
| Qol Medical, LLC | $51.98 | 2023-2025 | Sucraid |
| Ferring Pharmaceuticals INC. | $29.14 | 2024 | Rebyota |
| Merck Sharp & Dohme LLC | $23.11 | 2023 | Dificid |
| Fresenius Kabi USA, LLC | $21.43 | 2024 | Idacio |
| Mallinckrodt Hospital Products INC. | $18.95 | 2023 | Terlivaz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.49 | 2023 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.